Login Register Cart 0
Generic placeholder image

Current Protein & Peptide Science

Editor-in-Chief

ISSN (Print): 1389-2037
ISSN (Online): 1875-5550

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Epigenetic Regulator ASXL2: Structure, Function and its Predictive Value in Diseases

Author(s): Mengru Li, Lijun Xu, Rui Zhang and Chunming Dong*

Volume 24, Issue 1, 2023

Published on: 05 January, 2023

Page: [22 - 30] Pages: 9

DOI: 10.2174/1389203724666221208103516

Price: $65

Abstract

ASXL2, as a transcription regulator, is a research hotspot for tumor detection. The aberrant expression of ASXL2 protein has been mainly implicated in malignant hematological and heart diseases. To further explore the predictive value of ASXL2 in diseases, we reviewed the structure and function of ASXL2 protein, the post-translational modification mechanism, and the expression of ASXL2 protein in the pathogenesis of different diseases to provide a theoretical basis and support for the development of future treatments.

Keywords: ASXL2, structure, function, mechanism, epigenetic regulation, disease.

« Previous Next »
Graphical Abstract

[1]
Brunner, R.; Lai, H.L.; Deliu, Z.; Melman, E.; Geenen, D.; Wang, Q. ASXL2−/− mice exhibit de novo cardiomyocyte production during adulthood. J. Dev. Biol., 2016, 4(4), 32.
[http://dx.doi.org/10.3390/jdb4040032] [PMID: 29615595]
[2]
Lai, H.L.; Grachoff, M.; McGinley, A.L.; Khan, F.F.; Warren, C.M.; Chowdhury, S.A.K.; Wolska, B.M.; Solaro, R.J.; Geenen, D.L.; Wang, Q.T. Maintenance of adult cardiac function requires the chromatin factor ASXL2. J. Mol. Cell. Cardiol., 2012, 53(5), 734-741.
[http://dx.doi.org/10.1016/j.yjmcc.2012.08.014] [PMID: 23046516]
[3]
Li, J.; He, F.; Zhang, P.; Chen, S.; Shi, H.; Sun, Y.; Guo, Y.; Yang, H.; Man, N.; Greenblatt, S.; Li, Z.; Guo, Z.; Zhou, Y.; Wang, L.; Morey, L.; Williams, S.; Chen, X.; Wang, Q.T.; Nimer, S.D.; Yu, P.; Wang, Q.F.; Xu, M.; Yang, F.C. Loss of ASXL2 leads to myeloid malignancies in mice. Nat. Commun., 2017, 8(1), 15456.
[http://dx.doi.org/10.1038/ncomms15456] [PMID: 28593990]
[4]
Daou, S.; Hammond-Martel, I.; Mashtalir, N.; Barbour, H.; Gagnon, J.; Iannantuono, N.G.; Nkwe, N.S.; Motorina, A.; Pak, H.; Yu, H.; Wurtele, H.; Milot, E.; Mallette, F.A.; Carbone, M.; Affar, E.B. The BAP1/ASXL2 Histone H2A deubiquitinase complex regulates cell pro-liferation and is disrupted in cancer. J. Biol. Chem., 2015, 290(48), 28643-28663.
[http://dx.doi.org/10.1074/jbc.M115.661553] [PMID: 26416890]
[5]
Katoh, M. Functional and cancer genomics of ASXL family members. Br. J. Cancer, 2013, 109(2), 299-306.
[http://dx.doi.org/10.1038/bjc.2013.281] [PMID: 23736028]
[6]
Sinclair, D.A.; Milne, T.A.; Hodgson, J.W.; Shellard, J.; Salinas, C.A.; Kyba, M.; Randazzo, F.; Brock, H.W. The additional sex combs gene of drosophila encodes a chromatin protein that binds to shared and unique polycomb group sites on polytene chromosomes. Development, 1998, 125(7), 1207-1216.
[http://dx.doi.org/10.1242/dev.125.7.1207] [PMID: 9477319]
[7]
Katoh, M. Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine. Expert Rev. Proteomics, 2015, 12(3), 317-328.
[http://dx.doi.org/10.1586/14789450.2015.1033409] [PMID: 25835095]
[8]
Katoh, M.; Katoh, M. Identification and characterization of ASXL2 gene in silico. Int. J. Oncol., 2003, 23(3), 845-850.
[http://dx.doi.org/10.3892/ijo.23.3.845] [PMID: 12888926]
[9]
Katoh, M.; Igarashi, M.; Fukuda, H.; Nakagama, H.; Katoh, M. Cancer genetics and genomics of human FOX family genes. Cancer Lett., 2013, 328(2), 198-206.
[http://dx.doi.org/10.1016/j.canlet.2012.09.017] [PMID: 23022474]
[10]
Sanchez-Pulido, L.; Kong, L.; Ponting, C.P. A common ancestry for BAP1 and Uch37 regulators. Bioinformatics, 2012, 28(15), 1953-1956.
[http://dx.doi.org/10.1093/bioinformatics/bts319] [PMID: 22645167]
[11]
Fisher, C.; Berger, J.; Randazzo, F.; Brock, H.W. A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11. Gene, 2003, 306, 115-126.
[http://dx.doi.org/10.1016/S0378-1119(03)00430-X] [PMID: 12657473]
[12]
Scheuermann, J.C.; de Ayala Alonso, A.G.; Oktaba, K.; Ly-Hartig, N.; McGinty, R.K.; Fraterman, S.; Wilm, M.; Muir, T.W.; Müller, J. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature, 2010, 465(7295), 243-247.
[http://dx.doi.org/10.1038/nature08966] [PMID: 20436459]
[13]
Lee, S.W.; Cho, Y.S.; Na, J.M.; Park, U.H.; Kang, M.; Kim, E.J.; Um, S.J. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J. Biol. Chem., 2015, 290(10), 6008.
[http://dx.doi.org/10.1074/jbc.A109.065862] [PMID: 25750265]
[14]
Cho, Y.S.; Kim, E.J.; Park, U.H.; Sin, H.S.; Um, S.J. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J. Biol. Chem., 2006, 281(26), 17588-17598.
[http://dx.doi.org/10.1074/jbc.M512616200] [PMID: 16606617]
[15]
Sanchez, R.; Zhou, M.M. The PHD finger: A versatile epigenome reader. Trends Biochem. Sci., 2011, 36(7), 364-372.
[http://dx.doi.org/10.1016/j.tibs.2011.03.005] [PMID: 21514168]
[16]
Abdel-Wahab, O.; Adli, M.; LaFave, L.M.; Gao, J.; Hricik, T.; Shih, A.H.; Pandey, S.; Patel, J.P.; Chung, Y.R.; Koche, R.; Perna, F.; Zhao, X.; Taylor, J.E.; Park, C.Y.; Carroll, M.; Melnick, A.; Nimer, S.D.; Jaffe, J.D.; Aifantis, I.; Bernstein, B.E.; Levine, R.L. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell, 2012, 22(2), 180-193.
[http://dx.doi.org/10.1016/j.ccr.2012.06.032] [PMID: 22897849]
[17]
Piovesan, D.; Necci, M.; Escobedo, N.; Monzon, A.M.; Hatos, A.; Mičetić, I.; Quaglia, F.; Paladin, L.; Ramasamy, P.; Dosztányi, Z.; Vranken, W.F.; Davey, N.E.; Parisi, G.; Fuxreiter, M.; Tosatto, S.C.E. MobiDB: intrinsically disordered proteins in 2021. Nucleic Acids Res., 2021, 49(D1), D361-D367.
[http://dx.doi.org/10.1093/nar/gkaa1058] [PMID: 33237329]
[18]
Espinoza-Fonseca, L.M. Reconciling binding mechanisms of intrinsically disordered proteins. Biochem. Biophys. Res. Commun., 2009, 382(3), 479-482.
[http://dx.doi.org/10.1016/j.bbrc.2009.02.151] [PMID: 19265676]
[19]
Jiao, Z.; Zhao, X.; Wang, Y.; Wei, E.; Mei, S.; Liu, N.; Kong, X.; Shi, H. A de novo and novel nonsense variants in ASXL2 gene is associ-ated with Shashi-Pena syndrome. Eur. J. Med. Genet., 2022, 65(4), 104454.
[http://dx.doi.org/10.1016/j.ejmg.2022.104454] [PMID: 35182806]
[20]
Petruk, S.; Smith, S.T.; Sedkov, Y.; Mazo, A. Association of trxG and PcG proteins with the bxd maintenance element depends on tran-scriptional activity. Development, 2008, 135(14), 2383-2390.
[http://dx.doi.org/10.1242/dev.023275] [PMID: 18550707]
[21]
Baskind, H.A.; Na, L.; Ma, Q.; Patel, M.P.; Geenen, D.L.; Wang, Q.T. Functional conservation of ASXL2, a murine homolog for the Dro-sophila enhancer of trithorax and polycomb group gene Asx. PLoS One, 2009, 4(3), e4750.
[http://dx.doi.org/10.1371/journal.pone.0004750] [PMID: 19270745]
[22]
Gildea, J.J.; Lopez, R.; Shearn, A. A screen for new trithorax group genes identified little imaginal discs, the Drosophila melanogaster homologue of human retinoblastoma binding protein 2. Genetics, 2000, 156(2), 645-663.
[http://dx.doi.org/10.1093/genetics/156.2.645] [PMID: 11014813]
[23]
Eskeland, R.; Leeb, M.; Grimes, G.R.; Kress, C.; Boyle, S.; Sproul, D.; Gilbert, N.; Fan, Y.; Skoultchi, A.I.; Wutz, A.; Bickmore, W.A. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol. Cell, 2010, 38(3), 452-464.
[http://dx.doi.org/10.1016/j.molcel.2010.02.032] [PMID: 20471950]
[24]
Wang, H.; Wang, L.; Erdjument-Bromage, H.; Vidal, M.; Tempst, P.; Jones, R.S.; Zhang, Y. Role of histone H2A ubiquitination in Poly-comb silencing. Nature, 2004, 431(7010), 873-878.
[http://dx.doi.org/10.1038/nature02985] [PMID: 15386022]
[25]
Schuettengruber, B.; Cavalli, G. Recruitment of Polycomb group complexes and their role in the dynamic regulation of cell fate choice. Development, 2009, 136(21), 3531-3542.
[http://dx.doi.org/10.1242/dev.033902] [PMID: 19820181]
[26]
Margueron, R.; Reinberg, D. The polycomb complex PRC2 and its mark in life. Nature, 2011, 469(7330), 343-349.
[http://dx.doi.org/10.1038/nature09784] [PMID: 21248841]
[27]
Schuettengruber, B.; Bourbon, H.M.; Di Croce, L.; Cavalli, G. Genome regulation by polycomb and trithorax: 70 years and counting. Cell, 2017, 171(1), 34-57.
[http://dx.doi.org/10.1016/j.cell.2017.08.002] [PMID: 28938122]
[28]
Gaudet, P.; Livstone, M.S.; Lewis, S.E.; Thomas, P.D. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Brief. Bioinform., 2011, 12(5), 449-462.
[http://dx.doi.org/10.1093/bib/bbr042] [PMID: 21873635]
[29]
Park, U.H.; Yoon, S.K.; Park, T.; Kim, E.J.; Um, S.J. Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogene-sis via reciprocal regulation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem., 2011, 286(2), 1354-1363.
[http://dx.doi.org/10.1074/jbc.M110.177816] [PMID: 21047783]
[30]
Yamato, G.; Shiba, N.; Yoshida, K.; Shiraishi, Y.; Hara, Y.; Ohki, K.; Okubo, J.; Okuno, H.; Chiba, K.; Tanaka, H.; Kinoshita, A.; Mori-take, H.; Kiyokawa, N.; Tomizawa, D.; Park, M.; Sotomatsu, M.; Taga, T.; Adachi, S.; Tawa, A.; Horibe, K.; Arakawa, H.; Miyano, S.; Og-awa, S.; Hayashi, Y. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/RUNX1-RUNX1T1 and associated with a better prognosis. Genes Chromosomes Cancer, 2017, 56(5), 382-393.
[http://dx.doi.org/10.1002/gcc.22443] [PMID: 28063196]
[31]
Wang, R.; Wang, G. Protein modification and autophagy activation. Adv. Exp. Med. Biol., 2019, 1206, 237-259.
[http://dx.doi.org/10.1007/978-981-15-0602-4_12] [PMID: 31776989]
[32]
Hornbeck, P.V.; Zhang, B.; Murray, B.; Kornhauser, J.M.; Latham, V.; Skrzypek, E. PhosphoSitePlus, 2014: mutations, PTMs and recali-brations. Nucleic Acids Res., 2015, 43(D1), D512-D520.
[http://dx.doi.org/10.1093/nar/gku1267] [PMID: 25514926]
[33]
Faktor, J.; Pjechová, M.; Hernychová, L.; Vojtěšek, B. Protein ubiquitination research in oncology. Klin. Onkol., 2019, 32(Suppl. 3), 56-64.
[http://dx.doi.org/10.14735/amko20193S56] [PMID: 31627707]
[34]
Jensen, D.E.; Proctor, M.; Marquis, S.T.; Gardner, H.P.; Ha, S.I.; Chodosh, L.A.; Ishov, A.M.; Tommerup, N.; Vissing, H.; Sekido, Y.; Minna, J.; Borodovsky, A.; Schultz, D.C.; Wilkinson, K.D.; Maul, G.G.; Barlev, N.; Berger, S.L.; Prendergast, G.C.; Rauscher, F.J., III BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene, 1998, 16(9), 1097-1112.
[http://dx.doi.org/10.1038/sj.onc.1201861] [PMID: 9528852]
[35]
Campagne, A.; Lee, M.K.; Zielinski, D.; Michaud, A.; Le Corre, S.; Dingli, F.; Chen, H.; Shahidian, L.Z.; Vassilev, I.; Servant, N.; Loew, D.; Pasmant, E.; Postel-Vinay, S.; Wassef, M.; Margueron, R. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation. Nat. Commun., 2019, 10(1), 348.
[http://dx.doi.org/10.1038/s41467-018-08255-x] [PMID: 30664650]
[36]
Daou, S.; Barbour, H.; Ahmed, O.; Masclef, L.; Baril, C.; Sen Nkwe, N.; Tchelougou, D.; Uriarte, M.; Bonneil, E.; Ceccarelli, D.; Mashtalir, N.; Tanji, M.; Masson, J.Y.; Thibault, P.; Sicheri, F.; Yang, H.; Carbone, M.; Therrien, M.; Affar, E.B. Monoubiquitination of ASXLs con-trols the deubiquitinase activity of the tumor suppressor BAP1. Nat. Commun., 2018, 9(1), 4385.
[http://dx.doi.org/10.1038/s41467-018-06854-2] [PMID: 30349006]
[37]
Dai, X.; Ren, T.; Zhang, Y.; Nan, N. Methylation multiplicity and its clinical values in cancer. Expert Rev. Mol. Med., 2021, 23(2), e2.
[http://dx.doi.org/10.1017/erm.2021.4] [PMID: 33787478]
[38]
Lai, H.L.; Wang, Q.T. Additional sex combs-like 2 is required for polycomb repressive complex 2 binding at select targets. PLoS One, 2013, 8(9), e73983.
[http://dx.doi.org/10.1371/journal.pone.0073983] [PMID: 24040135]
[39]
Kuzmichev, A.; Nishioka, K.; Erdjument-Bromage, H.; Tempst, P.; Reinberg, D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev., 2002, 16(22), 2893-2905.
[http://dx.doi.org/10.1101/gad.1035902] [PMID: 12435631]
[40]
Park, U-H.; Kang, M-R.; Kim, E-J.; Kwon, Y-S.; Hur, W.; Yoon, S.K.; Song, B-J.; Park, J.H.; Hwang, J-T.; Jeong, J-C.; Um, S-J. ASXL2 promotes proliferation of breast cancer cells by linking ERα to histone methylation. Oncogene, 2016, 35(28), 3742-3752.
[http://dx.doi.org/10.1038/onc.2015.443] [PMID: 26640146]
[41]
Khan, F.F.; Li, Y.; Balyan, A.; Wang, Q.T. WTIP interacts with ASXL2 and blocks ASXL2-mediated activation of retinoic acid signaling. Biochem. Biophys. Res. Commun., 2014, 451(1), 101-106.
[http://dx.doi.org/10.1016/j.bbrc.2014.07.080] [PMID: 25065743]
[42]
Park, U.H.; Seong, M.; Kim, E.J.; Hur, W.; Kim, S.W.; Yoon, S.K.; Um, S.J. Reciprocal regulation of LXRα activity by ASXL1 and ASXL2 in lipogenesis. Biochem. Biophys. Res. Commun., 2014, 443(2), 489-494.
[http://dx.doi.org/10.1016/j.bbrc.2013.11.124] [PMID: 24321552]
[43]
Fang, J. The role of ASXL2 in the differentiation of mouse embryonic stem cell into cardiomyocytes and identification of its binding parterns; Tianjin Medical University, 2016.
[44]
Juliusson, G.; Hough, R. Leukemia. Prog. Tumor Res., 2016, 43, 87-100.
[http://dx.doi.org/10.1159/000447076] [PMID: 27595359]
[45]
Micol, J.B.; Duployez, N.; Pastore, A.; Williams, R.; Kim, E.; Lee, S.; Durham, B.; Chung, Y.R.; Cho, H.; Preudhomme, C.; Abdel-Wahab, O. ASXL2 is a novel mediator of RUNX1-ETO transcriptional function and collaborates with RUNX1-ETO to promote leukemogenesis. Blood, 2015, 126(23), 302.
[http://dx.doi.org/10.1182/blood.V126.23.302.302]
[46]
Metz, A.; Schanda, J.; Grez, M.; Wichmann, C.; Gohlke, H. From determinants of RUNX1/ETO tetramerization to small-molecule protein-protein interaction inhibitors targeting acute myeloid leukemia. J. Chem. Inf. Model., 2013, 53(9), 2197-2202.
[http://dx.doi.org/10.1021/ci400332e] [PMID: 23957251]
[47]
Micol, J.B.; Duployez, N.; Boissel, N.; Petit, A.; Geffroy, S.; Nibourel, O.; Lacombe, C.; Lapillonne, H.; Etancelin, P.; Figeac, M.; Renneville, A.; Castaigne, S.; Leverger, G.; Ifrah, N.; Dombret, H.; Preudhomme, C.; Abdel-Wahab, O.; Jourdan, E. Frequent ASXL2 mu-tations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood, 2014, 124(9), 1445-1449.
[http://dx.doi.org/10.1182/blood-2014-04-571018] [PMID: 24973361]
[48]
Jahn, N.; Agrawal, M.; Bullinger, L.; Weber, D.; Corbacioglu, A.; Gaidzik, V.I.; Schmalbrock, L.; Thol, F.; Heuser, M.; Krauter, J.; Göhring, G.; Kündgen, A.; Fiedler, W.; Wattad, M.; Held, G.; Köhne, C-H.; Horst, H-A.; Lübbert, M.; Ganser, A.; Schlenk, R.F.; Döhner, H.; Döhner, K.; Paschka, P. Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group. Leukemia, 2017, 31(4), 1012-1015.
[http://dx.doi.org/10.1038/leu.2017.18] [PMID: 28090090]
[49]
Cui, R.; Yang, L.; Wang, Y.; Zhong, M.; Yu, M.; Chen, B. Elevated expression of ASXL2 is associated with poor prognosis in colorectal cancer by enhancing tumorigenesis and inducing cell proliferation. Cancer Manag. Res., 2020, 12, 10221-10228.
[http://dx.doi.org/10.2147/CMAR.S266083] [PMID: 33116876]
[50]
Wang, G.; Yang, L.; Gao, J.; Mu, H.; Song, Y.; Jiang, X.; Chen, B.; Cui, R. Identification of candidate biomarker ASXL2 and its predictive value in pancreatic carcinoma. Front. Oncol., 2021, 11, 736694.
[http://dx.doi.org/10.3389/fonc.2021.736694] [PMID: 34692512]
[51]
Izawa, T.; Rohatgi, N.; Fukunaga, T.; Wang, Q.T.; Silva, M.J.; Gardner, M.J.; McDaniel, M.L.; Abumrad, N.A.; Semenkovich, C.F.; Teitel-baum, S.L.; Zou, W. ASXL2 regulates glucose, lipid, and skeletal homeostasis. Cell Rep., 2015, 11(10), 1625-1637.
[http://dx.doi.org/10.1016/j.celrep.2015.05.019] [PMID: 26051940]
[52]
Zou, W.; Rohatgi, N.; Brestoff, J.R.; Moley, J.R.; Li, Y.; Williams, J.W.; Alippe, Y.; Pan, H.; Pietka, T.A.; Mbalaviele, G.; Newberry, E.P.; Davidson, N.O.; Dey, A.; Shoghi, K.I.; Head, R.D.; Wickline, S.A.; Randolph, G.J.; Abumrad, N.A.; Teitelbaum, S.L. Myeloid-specific ASXL2 deletion limits diet-induced obesity by regulating energy expenditure. J. Clin. Invest., 2020, 130(5), 2644-2656.
[http://dx.doi.org/10.1172/JCI128687] [PMID: 32310225]
[53]
Hu, Z.; Zhang, Z.; Teng, F.; Feng, J.; Wu, X.; Chang, Q. Role of ASXL2 in non alcoholic steatohepatitis related hepatocellular carcinoma developed from diabetes. Int. J. Mol. Med., 2020, 47(1), 101-112.
[http://dx.doi.org/10.3892/ijmm.2020.4782] [PMID: 33155659]
[54]
Alqaisi, D.; Hassona, Y. Oral findings and healthcare management in Shashi‐Pena syndrome. Spec. Care Dentist., 2022, 42(4), 432-436.
[http://dx.doi.org/10.1111/scd.12689] [PMID: 34902171]
[55]
Wang, Y.; Tan, J.; Wang, Y.; Liu, A.; Qiao, F.; Huang, M.; Zhang, C.; Zhou, J.; Hu, P.; Xu, Z. Diagnosis of shashi-pena syndrome caused by chromosomal rearrangement using nanopore sequencing. Neurol. Genet., 2021, 7(6), e635.
[http://dx.doi.org/10.1212/NXG.0000000000000635] [PMID: 34841066]
[56]
Micol, J.B.; Pastore, A.; Inoue, D.; Duployez, N.; Kim, E.; Lee, S.C.W.; Durham, B.H.; Chung, Y.R.; Cho, H.; Zhang, X.J.; Yoshimi, A.; Krivtsov, A.; Koche, R.; Solary, E.; Sinha, A.; Preudhomme, C.; Abdel-Wahab, O. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat. Commun., 2017, 8(1), 15429.
[http://dx.doi.org/10.1038/ncomms15429] [PMID: 28516957]
[57]
Madan, V.; Han, L.; Hattori, N.; Teoh, W.W.; Mayakonda, A.; Sun, Q.Y.; Ding, L.W.; Nordin, H.B.M.; Lim, S.L.; Shyamsunder, P.; Dakle, P.; Sundaresan, J.; Doan, N.B.; Sanada, M.; Sato-Otsubo, A.; Meggendorfer, M.; Yang, H.; Said, J.W.; Ogawa, S.; Haferlach, T.; Liang, D.C.; Shih, L.Y.; Nakamaki, T.; Wang, Q.T.; Koeffler, H.P. ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion. Haematologica, 2018, 103(12), 1980-1990.
[http://dx.doi.org/10.3324/haematol.2018.189928] [PMID: 30093396]
[58]
Micol, J.B.; Abdel-Wahab, O. The Role of Additional Sex Combs-Like Proteins in Cancer. Cold Spring Harb. Perspect. Med., 2016, 6(10), a026526.
[http://dx.doi.org/10.1101/cshperspect.a026526] [PMID: 27527698]

Rights & Permissions Print Cite
Article Metrics
36
2
© 2024 Bentham Science Publishers | Privacy Policy